Akihiro Hisaka

Dr. Akihiro Hisaka

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Open access
KMKazuya Maeda
Kazuya Maeda
AHAkihiro Hisaka
Akihiro Hisaka
KIKiyomi Ito
Kiyomi Ito
YOYoshiyuki Ohno
Yoshiyuki Ohno
AIAkihiro Ishiguro
Akihiro Ishiguro
NNNaomi Nagai
Naomi Nagai
During new drug development, clinical drug interaction studies are carried out in accordance with the mechanism of potential drug interactions evaluated by in vitro studies. The obtained information should be provided efficiently to medical experts through package inserts and various information materials after the drug's launch. A recently updated Japanese guideline presents general procedures that are considered scientifically valid at the present moment. In this review, we aim to highlight the viewpoints of the Japanese guideline and enumerate drugs that were involved or are anticipated to be involved in evident pharmacokinetic drug interactions and classify them by their clearance pathway and potential intensity based on systematic reviews of the literature. The classification would be informative for designing clinical studies during the development stage, and the appropriate management of drug interactions in clinical practice.

1 October 2014 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
AHAkihiro Hisaka
Akihiro Hisaka
MNMikiko Nakamura
Mikiko Nakamura
ATAyako Tsukihashi
Ayako Tsukihashi
SKSaori Koh
Saori Koh
HSHiroshi Suzuki
Hiroshi Suzuki
In this study, we developed the drug–drug interaction (DDI) method as a new assessment technique of intestinal availability (FG, the fraction of drug transferred from the intestinal enterocytes into the liver, escaping from intestinal metabolism) based on the clearance theory. This method evaluates FG from changes caused by DDIs in the area under the blood concentration-time curve and in the elimination half-life of victim drugs. Application of the DDI method to data from the literature revealed that the mean and S.D. of FG values for 20 substrate drugs of CYP3A was 0.56 ± 0.29, whereas that for 8 substrate drugs of CYP2C9, CYP2C19, and CYP2D6 was 0.86 ± 0.11. These results were consistent with the fact that intestinal metabolism is mediated predominantly by CYP3A. The DDI method showed reasonable correlations with the conventional i.v./p.o. method and the grape fruit juice (GFJ) method (coefficients of determination of 0.41 and 0.81, respectively). The i.v./p.o. method was more susceptible to fluctuations in the hepatic blood flow rate compared with the DDI and GFJ methods. The DDI method evaluates FG separating from the absorption ratio (FA) although it requires approximation of FA. Since preciseness of approximation of FA does not greatly affect the evaluation of FG by the DDI method, we proposed a reasonable approximation method of FA for the evaluation of FG in the DDI method. The DDI method would be applicable to a broad range of situations in which various DDI data are utilizable.


4 December 2020 in Cancers
Verified
Journal Article
Open access
PDF file
RCRiki Cho
Riki Cho
YSYu Sakurai
Yu Sakurai
HJHaleigh Sakura Jones
Haleigh Sakura Jones
HAHidetaka Akita
Hidetaka Akita
AHAkihiro Hisaka
Akihiro Hisaka
Hiroto HatakeyamaHiroto Hatakeyama
Hiroto Hatakeyama
Despite the promising anticancer effects of immune checkpoint inhibitors, their low objective response rate remains to be resolved; thus, combination therapies have been investigated. We investigated the combination of an anti-programmed cell death 1 (aPD-1) monoclonal antibody with the knockdown of vascular endothelial factor receptor 2 (VEGFR2) on tumor endothelial cells to overcome resistance to immune checkpoint inhibitors and improve the objective response rate. The successful delivery of small interfering RNA to tumor endothelial cells was achieved by RGD peptide-modified lipid nanoparticles composed of a novel, pH-sensitive, and biodegradable ssPalmO-Phe. RGD-modified lipid nanoparticles efficiently induced the knockdown of VEGFR2 in tumor endothelial cells (TECs), which induced vascular normalization. The combination of a PD-1 monoclonal antibody with Vegfr2 knockdown enhanced CD8+ T cell infiltration into tumors and successfully suppressed tumor growth and improved response rate compared with monotherapy. Our combination approach provides a promising strategy to improve therapeutic outcomes in immune checkpoint inhibitor-resistant cancers.

Verified
Journal Article
Open access
PDF file
AHAkihiro Hisaka
Akihiro Hisaka
HYHideki Yoshioka
Hideki Yoshioka
Hiroto HatakeyamaHiroto Hatakeyama
Hiroto Hatakeyama
HSHiromi Sato
Hiromi Sato
YOYoshihiro Onouchi
Yoshihiro Onouchi
N*Naohiko Anzai *
Naohiko Anzai *
Global differences in changes in the numbers of population-adjusted daily test-positive cases (NPDP) and deaths (NPDD) by COVID-19 were analyzed for 49 countries, including developed and developing countries. The changes as a proportion of national population were compared, adjusting by the beginning of test-positive cases increase (BPI) or deaths increase (BDI). Remarkable regional differences of more than 100-fold in NPDP and NPDD were observed. The trajectories of NPDD after BDI increased exponentially within 20 days in most countries. Machine learning analysis suggested that NPDD on 30 days after BDI was the highest in developed Western countries (1180 persons per hundred million), followed by countries in the Middle East (128), Latin America (97), and Asia (7). Furthermore, in Western countries with positive rates of the PCR test of less than 7.0%, the increase in NPDP was slowing-down two weeks after BPI, and subsequent NPDD was only 15% compared with those with higher positive rates, which suggested that the situation of testing might have affected the velocity of COVID-19 spread. The causes behind remarkable differences between regions possibly include genetic factors of inhabitants because distributions of the race and of the observed infection increasing rates were in good agreement globally.

1 April 2015 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
PDF file
HAHirotaka Ando
Hirotaka Ando
AHAkihiro Hisaka
Akihiro Hisaka
HSHiroshi Suzuki
Hiroshi Suzuki
This study aimed to construct a new local pharmacokinetic model of gastrointestinal absorption, the translocation model (TLM), using an anatomically relevant, minimally segmented structure to explain linear and nonlinear intestinal absorption, metabolism, and transport. The TLM was based on the concept of a single absorption site that flexibly moves, expands, and shrinks along with the length of the gastrointestinal tract after the intake of an oral dose. The structure of the small intestine is continuous, and various time- and location-dependent issues are freely incorporated in the analysis. Since the model has only one absorption site, understanding and modification of factors affecting absorption are simple. The absorption site is composed of four compartments: solid drug in the lumen, solution drug in the lumen, concentration in the enterocytes, and concentration in the lamina propria. The lamina propria includes the blood capillaries. Blood flow in the absorption site of the lamina propria appropriately accounts for the absorption. In the TLM, the permeability of the apical membrane and that of the basolateral membrane are distinct. By considering plicate, villi, and microvilli expansions of the surface area, the apparent permeability measured in Caco-2 experiments was converted to the effective permeability in vivo. The intestinal availability, bioavailability, and dose product of intestinal availability and absorption rate relationship of the model drugs were well explained using the TLM. The TLM would be a useful tool for the consideration of local pharmacokinetics in the gastrointestinal tract in various situations.